Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

Vaccines preventing tuberculosis disease progression have shown promising results in recent trials. Here, the authors use mathematical modelling to estimate that this type of vaccine could avert 10% of cases of rifampicin-resistant tuberculosis and 7% of deaths from 2020-2035.

Guardado en:

Detalles Bibliográficos
Autores principales:	Han Fu, Joseph A. Lewnard, Isabel Frost, Ramanan Laxminarayan, Nimalan Arinaminpathy
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/8295a488396e416da2b87fee41569db6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8295a488396e416da2b87fee41569db6
record_format	dspace
spelling	oai:doaj.org-article:8295a488396e416da2b87fee41569db62021-12-02T13:51:03ZModelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine10.1038/s41467-020-20731-x2041-1723https://doaj.org/article/8295a488396e416da2b87fee41569db62021-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-20731-xhttps://doaj.org/toc/2041-1723Vaccines preventing tuberculosis disease progression have shown promising results in recent trials. Here, the authors use mathematical modelling to estimate that this type of vaccine could avert 10% of cases of rifampicin-resistant tuberculosis and 7% of deaths from 2020-2035.Han FuJoseph A. LewnardIsabel FrostRamanan LaxminarayanNimalan ArinaminpathyNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Han Fu Joseph A. Lewnard Isabel Frost Ramanan Laxminarayan Nimalan Arinaminpathy Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
description	Vaccines preventing tuberculosis disease progression have shown promising results in recent trials. Here, the authors use mathematical modelling to estimate that this type of vaccine could avert 10% of cases of rifampicin-resistant tuberculosis and 7% of deaths from 2020-2035.
format	article
author	Han Fu Joseph A. Lewnard Isabel Frost Ramanan Laxminarayan Nimalan Arinaminpathy
author_facet	Han Fu Joseph A. Lewnard Isabel Frost Ramanan Laxminarayan Nimalan Arinaminpathy
author_sort	Han Fu
title	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
title_short	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
title_full	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
title_fullStr	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
title_full_unstemmed	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
title_sort	modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8295a488396e416da2b87fee41569db6
work_keys_str_mv	AT hanfu modellingtheglobalburdenofdrugresistanttuberculosisavertablebyapostexposurevaccine AT josephalewnard modellingtheglobalburdenofdrugresistanttuberculosisavertablebyapostexposurevaccine AT isabelfrost modellingtheglobalburdenofdrugresistanttuberculosisavertablebyapostexposurevaccine AT ramananlaxminarayan modellingtheglobalburdenofdrugresistanttuberculosisavertablebyapostexposurevaccine AT nimalanarinaminpathy modellingtheglobalburdenofdrugresistanttuberculosisavertablebyapostexposurevaccine
_version_	1718392448455016448

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

Ejemplares similares